Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260845 | 0.83 | ALDH1A1 (0.34) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25438598 | 0.79 | ALDH1A1 (0.31) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL27008050 | 0.79 | ALDH1A1 (0.31) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL27008199 | 0.78 | SMPD3 (0.32) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL26814901 | 0.78 | KDM4E (0.33) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25435839 | 0.78 | HPGD (0.31) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL27008131 | 0.77 | ALDH1A1 (0.30) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL18870689 | 0.76 | — | — | |
| SCHEMBL25151318 | 0.75 | IRAK4 (0.33) | — | |
| SCHEMBL27008088 | 0.75 | GRM4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308576-B1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4308576-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022194801-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018163-A1 | NEW THIAZOLOPYRIMIDINONE DERIVATIVES | NDUFS3, FOXM1, MT-ND1 | ALDH1A1 52/4885HPGD 2371/4885HSD17B10 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.